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I
n recent years, there have been important advances in the
understanding of diffuse parenchymal lung diseases,
especially in relation to the idiopathic interstitial pneumo-
nias, including idiopathic pulmonary fibrosis and nonspecific
interstitial pneumonia. Among other diffuse parenchymal lung
diseases, the topics of particular interest centred on hypersen-
sitivity pneumonia, parenchymal disease associated with
connective tissue disease, lymphangioleiomyomatosis and
pulmonary hypertension. Insights on disease prevalence,
diagnosis, prognostic evaluation, and management for the
granulomatous diseases have not been discussed in this
review.
IDIOPATHIC PULMONARY FIBROSIS
Epidemiology
Idiopathic pulmonary fibrosis (IPF) is a devastating disease,
with a 5-yr survival rate of only 20–30% following diagnosis.
Pulmonary fibrosis remains a significant health problem
whose true incidence and prevalence has been believed to be
increasing in recent years. Using a database from the National
Center for Health Statistics, OLSON et al. [1] clearly show for the
first time that the mortality rates have increased from 1992 to
2003. Although these data do not confirm that the prevalence is
increasing, they do suggest that there have been improvements
in reporting and identification of fibrotic lung diseases. The
age-adjusted mortality increased for both sexes, and the
authors of this report suggest that this trend will continue.
The most common cause of death in people with IPF is
progression of their underlying lung disease, but there is
evidence that the incidence of other diseases, such as lung
cancer, may be increased in people with IPF [2–5]. This is
interesting, because such associations may shed light on the
aetiology and/or pathogenesis of IPF, and highlight the need
for a comprehensive approach to the care of people with IPF
[6]. A previous review by PANOS et al. [2] highlighted a possible
increase in cardiovascular disease in people with IPF, and
evidence supporting this observation comes from a recent
uncontrolled autopsy study in which nine out of 42 people
with IPF died from a cardiovascular event [4]. Furthermore, in
a study of 630 people referred for lung transplantation, KIZER et
al. [7] found that people with IPF were more than twice as
likely to have angiographic evidence of coronary artery disease
as people with nonfibrotic lung diseases. Findings from a
recent study suggest that patients with IPF have a marked
relative increase in the risk of vascular disease (angina, acute
coronary syndromes, and deep-vein thrombosis) [8], and this
should be considered during the routine care of these patients.
Prognostic evaluation in IPF
The clinical course of patients with IPF is variable and can
display long periods of stability, a steady gradual decline,
and/or periods of acute deterioration [3, 9]. This unpredictable
nature of usual interstitial pneumonia (UIP)/IPF highlights the
importance of identifying factors that can help refine the
prognosis for patients at the time of initial diagnosis. One of
the most striking findings of a recent study [10] is the variable
high-resolution computed tomography (HRCT) appearance
of UIP despite very rigid histopathological criteria. It would
have been expected that the rigid inclusion criteria define a
more homogeneous patient population with similar HRCT
features. Interestingly, only approximately one-third of HRCTs
showed definite IPF (figs 1 and 2) and approximately one-third
suggested an alternative diagnosis, such as nonspecific inter-
stitial pneumonia (NSIP) (fig. 3), or were unclassifiable. This
study highlights the critical importance of a surgical lung biopsy
in making an accurate diagnosis in patients without definite
HRCT appearance of UIP, even when an alternative diagnosis,
such as NSIP, is suspected [11]. This study also sheds additional
light on the role of HRCT in determining prognosis for patients
with UIP/IPF. The survival of patients within each HRCT
category was statistically similar, although the median survival
was shortest for the definite UIP group (35 months), inter-
mediate for the consistent with UIP group (43 months), and
longest for the alternative diagnosis group (112 months). The
lack of statistical significance in the study could be due to
limited sample size or selection bias [10].
A decrease in forced vital capacity (FVC) of at least 10% or
diffusing capacity for carbon monoxide (DL,CO) of at least 15%
over 6 or 12 months is associated with decreased survival [12, 13].
Although change in FVC is a good surrogate for subsequent
mortality, it is imperfect as some patients die without a 10%
decline in FVC, whereas others can live for prolonged periods
even after a 10% decline in FVC [3, 14]. Distance walked
during 6-min walk test (6MWT) was an important prognostic
factor in recent studies [15, 16]; however, the prognostic value
of desaturation and distance walked during 6MWT remain
controversial. Maximal oxygen uptake (V9O2,max) is an inte-
grated measure of cardiovascular, respiratory, and neuro-
muscular function. In a recent study, a baseline V9O2,max
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,8.3 mL?kg-1?min-1 threshold was identified in IPF patients,
below which the risk of death was greatly increased [17].
An area of debate is the utility of bronchoalveolar lavage (BAL)
for diagnosis and/or prognosis in IPF. Although the pattern of
cells recovered with this procedure may narrow the differ-
ential diagnosis of interstitial pneumonias, its role in IPF
remains controversial. A previous report suggested that BAL
lymphocytosis .20% is associated with response to anti-
inflammatory therapy and improved survival in biopsy-
proven patients with IPF [18]. KINDER et al.[19] report that a
low percentage of neutrophils (,3%) is associated with
favourable outcomes, and that each doubling of baseline BAL
fluid neutrophil percentage is associated with a 30% increased
risk of mortality during the first year after diagnosis. The
presence of BAL lymphocytosis was shown to shift diagnostic
probabilities from IPF to hypersensitivity pneumonitis or
sarcoidosis. In patients with IPF, as then diagnosed, BAL
lymphocytosis denoted a better outcome from treatment. These
data suggest that the utility of BAL for risk stratification of
patients with IPF should be reconsidered [20, 21]. There may
be a complementary role for BAL with cellular differentials in
diagnosing interstitial lung diseases (ILDs) in a minority of
subjects. In patients suspected of IPF clinically, without classic
computed tomography features for IPF (absence of honey-
combing or a substantial amount of ground-glass opacification
outside of areas of reticulation) and who are at high risk for
surgical lung biopsy, BAL may be a reasonable tool to use.
Surfactant protein (SP)-A and SP-D are members of the
collectin family. Secreted primarily by alveolar epithelial type
II pneumocytes, plasma SP-A and SP-D levels appear to
increase early after breakdown in the alveolar epithelium.
SP-A has been shown to be present in abnormal amounts in the
BAL fluid of patients with IPF [22]. In a recent study, KINDER et
al. [23] demonstrated that serum SP-A level at the time of
diagnosis of IPF is a strong independent predictor of time to
death or to lung transplantation, particularly during the first
year of follow-up. Increased serum SP-A concentrations may
identify a subset of patients with more ‘‘active’’ disease that
increases the risk of death in the following year and was not
predicted by other baseline, noninvasive clinical predictors,
such as lung function test results.
Acute exacerbation of IPF: radiological/pathological
aspects and pathogenesis
Acute exacerbation of IPF (IPF-AE) is a challenging problem,
defined as a rapid deterioration of IPF during the course of the
disease that cannot be attributed to infection, pulmonary
embolism or heart failure; mortality rates may be as high as 60
to 70% over 3 to 6 months [24]. There is no known effective
therapy for this devastating disease, and potential new
approaches [25] in well-designed clinical trials are urgently
needed. The pathological hallmark of IPF-AE is diffuse
alveolar damage (DAD) superimposed on the UIP pattern
FIGURE 1. Definite usual interstitial pneumonia pattern. High-resolution
computed tomography demonstrates honeycombing in a predominantly peripheral
distribution.
FIGURE 2. A pattern consistent with usual interstitial pneumonia pattern. High-
resolution computed tomography image demonstrates irregular intralobular
reticular opacity, ground-glass opacity and traction bronchiectasis in a predomi-
nantly peripheral distribution. There is no extensive honeycombing.
FIGURE 3. Pattern high-resolution computed tomography consistent with
nonspecific interstitial pneumonia in a patient with histological diagnosis of usual
interstitial pneumonia. Ground-glass opacities, reticulation and marked traction
bronchiectasis are present in the lung.
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characteristic in IPF [26]. IPF-AE can occur at any time during
the disease course, and the risk of an exacerbation does not
appear to be linked to the level of pulmonary function
derangement, age or smoking history [27]. The histological
findings from lung biopsy specimens show variable aspects;
the typical UIP pattern is associated with signs of acute lesions,
such as DAD with or without hyaline membranes, numerous
fibroblastic foci, organising pneumonia, and haemorrhage with
capillaritis [26, 28]. CHURG et al. [29] described that three
microscopic patterns of acute lung injury were seen in IPF-AE:
DAD, organising pneumonia and a pattern of numerous very
large fibroblastic foci superimposed on underlying fibrosis,
and that patients with organising pneumonia or extensive
fibroblastic foci as the acute pattern seem to do better than
those with DAD. New areas of ground-glass opacities can be
identified on HRCT during IPF-AE, and the extent and pattern
of these are linked to prognosis [30]. In the IPF-AE, two basic
computed tomography patterns may be classified: new areas of
parenchymal opacification mainly within the peripheral region
with relatively limited damage, and new areas of parenchymal
opacification that spread rapidly throughout the lung with a
fulminant clinical course. AKIRA et al. [30] demonstrated that
survival was worse for patients with HRCT diffuse pattern
than for those with both peripheral and multifocal pattern.
Computed tomography scans of multifocal pattern were
obtained in the earlier phase of acute exacerbation compared
with those of diffuse pattern and multifocal pattern evolved
into diffuse pattern for a short period. Multifocal pattern is
considered to be the early phase of diffuse pattern. Peripheral
pattern does not evolve into diffuse pattern for a short period.
On the basis of computed tomography–pathological correla-
tion in this study, diffuse pattern corresponded to DAD,
whereas peripheral pattern mainly correlated with organising
pneumonia or numerous fibroblastic foci. The computed
tomography extent and patterns had a higher predictive value
regarding patient survival than did the clinical and laboratory
data [30].
Little is known about the pathogenesis of IPF-AE. Along with
histopathology of DAD, there is evidence of loss of alveolar
epithelial cell integrity [28]. It has been suggested that IPF-AE
may represent a response to a clinically occult infection [31, 32]
but direct evidence of an association with infections is still
missing [33]. To generate new hypotheses regarding the
molecular events that underlie IPF-AE and to identify new
potential biomarkers for this syndrome, a recent study
analysed the global gene expression patterns in the lungs of
patients undergoing IPF-AE and compared them with stable
IPF and control lungs [34]. Compared with control samples,
IPF and IPF-AE lungs exhibited similar gene expression
signatures. However, on direct comparison of IPF and IPF-
AE the study identified differentially expressed genes and
chose to focus the validation on CCNA2 and a-defensins.
CCNA2, a general regulator of the cell cycle, was among the
most upregulated genes in IPF-AE. Increased CCNA2 protein
expression was localised to proliferating epithelial cells but not
to mesenchymal cells. The overexpression and localisation of
CCNA2 to epithelial cells but not to mesenchymal cells
suggests that IPF-AE is probably an extension of the epithelial
injury and dysregulation that characterises IPF [35] and
definitely is not a result of uncontrolled fibroblast proliferation.
Gene expression patterns indicate that IPF-AE represents an
extension of the molecular process that underlies IPF and not a
new process. Gene expression levels of a-defensins were
upregulated in IPF-AE and their protein expression was
localised to the alveolar epithelium in IPF-AE. Plasma a-
defensin concentrations were higher in patients with IPF-AE
compared with those with stable IPF or control subjects. Taken
together, these results indicate the central role of the
pulmonary epithelium in IPF-AE and suggest a potential role
for a-defensins as peripheral blood biomarkers in IPF-AE [34].
New insights in therapy and pathogenesis of IPF
IPF is among the most therapeutically challenging lung
disorders. No pharmacological agent improves survival in
IPF and the search for an effective agent to treat IPF continues.
Immunosuppressive treatment regimens have been used in the
treatment of IPF; however, there is little evidence to support
their efficacy and safety. As more has been discovered about
the pathophysiological processes underlying IPF, new ther-
apeutic approaches have been explored and controlled clinical
trials conducted on these new therapies. For example, there is
accumulating evidence that endothelin (ET)-1, a potent
vasoconstrictor, plays an important role in the aetiology of
IPF and that drugs that target ET-1 may be of benefit in
patients with IPF. Bosentan, an oral dual receptor antagonist of
ET-1, represents an interesting prospect for evaluation as a
treatment for IPF. The randomised, placebo-controlled BUILD
(Bosentan Use in Interstitial Lung Disease)-1 trial evaluated the
efficacy, safety, and tolerability of bosentan in patients with
IPF without evidence of pulmonary hypertension (PH) [36].
Although bosentan did not affect the exercise capacity of
patients in this trial, as measured by a modified 6MWT, it
demonstrated promising effects on time to disease progression
or death, with a more pronounced treatment effect in the
subset of patients entered on the basis of biopsy-confirmed IPF.
These observations are being investigated further in the
randomised, placebo-controlled, event-driven morbidity/mor-
tality study, BUILD-3. Results of this study have been
disclosed recently. While there was a consistent trend in
favour of bosentan, the primary end-point, time to disease
worsening or death, was not met. Studies with macitentan, a
new, potent (,10 times more potent than bosentan) dual
receptor antagonist of ET-1, and ambrisentan, a more selective
ET-1 receptor antagonist, are ongoing.
The effect of interferon (IFN)-c in patients with IPF was also
assessed in the multicentre, double-blind, randomised
INSPIRE study with survival time as the primary end-point
[37]. However, this study was stopped prematurely following
a planned interim analysis. The results showed that overall
survival had crossed the predefined stopping boundary for
lack of benefit, although among the 826 randomised patients
there was not a statistically significant difference between
treatment groups in overall mortality (14.5% in the IFN-c
group compared with 12.7% in the placebo group).
RAGHU et al. [38] report an important, albeit negative, result in a
well-designed randomised controlled trial of tumour necrosis
factor (TNF)-a antagonist therapy in patients with IPF. The
negative result of the etanercept study is unequivocal because
the trialists used a placebo-controlled design, which is ethically
acceptable when no known effective therapy exists. It would be
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less appropriate to conduct a trial in which both groups receive
therapy of unknown efficacy (even though standard of care);
this study design makes results regarding the experimental
intervention impossible to interpret. It remains unclear, for
example, whether N-acetylcysteine has a beneficial effect in
patients with IPF because both groups received prednisone
and azathioprine [39]. The placebo-controlled design of the
etanercept trial is an important benchmark for future IPF
studies [40]. Because this study included only a modest
number of subjects, it was not altogether surprising that there
were no statistically significant differences between treatment
groups in the three primary end-points: changes in FVC %
predicted, DL,CO haemoglobin % predicted and alveolar–
arterial oxygen tension difference (at rest) at 48 weeks.
However, a consistent trend in favour of etanercept was
observed in several lung function and quality-of-life measures.
This study was limited by a lack of power, which minimised
the chance of achieving a positive result. The results observed
here support further investigation of TNF antagonists in
clinical trials with adequate sample size and controls [38]. In
a randomised, placebo-controlled trial of patients with mild to
moderate IPF followed for 96 weeks, imatinib did not affect
survival or lung function [41]. A randomised, controlled pilot
trial compared oral cotrimoxazole to a placebo in 20 patients
with advanced progressive fibrosing lung diseases over a
period of 3 months, followed by 6 weeks of pulmonary
rehabilitation before decoding [42]. Positive findings were
reported for the shuttle-walking test as well as for lung
function measures and dyspnoea score. The mechanism by
which co-trimoxazole may improve or stabilise idiopathic
interstitial pneumonia (IIP) is unknown but several possibi-
lities exist: 1) antibacterial action: subclinical infection may
influence inflammatory mechanisms and the fibrotic process;
2) antifungal actions: co-trimoxazone is active against fungi
and protozoans, including pneumocystis, and many patients
with IPF experienced long-term immunosuppression; and 3)
immune modulating: co-trimoxazole is an effective monother-
apy for the treatment of Wegener’s granulomatosis and its anti-
staphylococcal action and anti-inflammatory properties are
hypothesised important mechanisms. Despite the many
limitations of this preliminary pilot study, the utility of
antibiotic or antifungal therapy as adjunctive therapy for
advanced fibrotic lung disease may merit further investigation.
Similar to other chronic pulmonary diseases (e.g. emphysema
or even PH), there is emerging evidence that pulmonary
rehabilitation may improve exercise tolerance, health status
and quality of life in patients with diffuse parenchymal lung
diseases (DPLDs) [43–45]. These studies were limited, how-
ever, by the small numbers of patients enrolled and the lack of
any benefit beyond 6 months [44]. Adequately designed and
powered studies are needed to confirm these initial results and
to assess the contribution of rehabilitation as part of a
comprehensive treatment approach to patients with DPLDs.
Publication of results of multicentre, double-blind, placebo-
controlled randomised study on pirfenidone treatment in IPF
(CAPACITY trial) are pending. A total of 779 patients were
enrolled in the CAPACITY trials at 110 sites in 11 countries.
Preliminary results show a significantly smaller loss of lung
function after 72 weeks than placebo in one study (CAPACITY 2),
but the other almost identical trial (CAPACITY 1) did not
show such benefit in the primary end-point; supportive
evidence of a pirfenidone treatment effect was observed on a
number of secondary end-points in CAPACITY 1 [46]. Data
from these two studies suggests that pirfenidone has a positive
treatment effect on patients with IPF. The CAPACITY trials
follow a phase III clinical study conducted in Japan which
demonstrated the ability of pirfenidone to reduce the decline
of lung capacity and improve progression-free survival [47]
and served as the basis for the Japanese regulatory authorities’
approval of the drug for the treatment of IPF in Japan. The
Food and Drug Administration evaluation of pirfenidone for
IPF treatment in the USA is ongoing.
Despite a large number of new therapeutic agents being
evaluated in clinical trials, there is no effective treatment for
IPF patients. The recurrent and frustrating observation that
steroids and immunosuppressants are of limited help in IPF,
coincident with new insights into genetic aberrations in
familial forms of IIP, caused a paradigm shift with respect to
the pathogenetic mechanism of IPF: what was once believed to
be triggered by chronic inflammation is now believed to be
caused by repeated alveolar epithelial cell injury. Like many
other complex human diseases, a single aetiology or aberrant
signalling pathway may not be causal in all cases [48]. As its
name suggests, IPF is a disorder with an enigmatic pathogen-
esis. It is currently believed that IPF is an epithelial–fibroblastic
disease, in which unknown endogenous or environmental
stimuli disrupt the homeostasis of alveolar epithelial cells,
resulting in diffuse epithelial cell activation and aberrant
epithelial repair [49]. It is already known that familial IPF
occurs as an autosomal dominant disorder with variable
penetrance [50–52]. To date, only three candidate genetic
mutations have emerged from studies of pulmonary fibrosis in
affected families. The evidence for genetic factors in sporadic
IPF is much less compelling. LOYD [53] explores mutations in
the genes encoding SP-C (SFTPC) and components of the
telomerase gene, i.e. human telomerase reverse transcriptase
and telomerase RNA component. Further research in this field
will surely reveal other important candidates and will one day
help to identify future therapeutic targets for this hugely
challenging disease. CRONKHITE et al. [54] describe the
unexpected and fascinating finding that telomeres are severely
shortened in peripheral leukocytes in approximately one-
quarter of sporadic and familial cases of pulmonary fibrosis. In
families with IPF with a genomic telomerase mutation as the
basis, the parenchymal lung cells have a mutant telomerase (an
enzyme that is responsible for maintenance of telomere lengths
in replicating stem/progenitor cells), suggesting the possibility
that cell demise or limited regenerative capacity, or both, may
be a central feature that may initiate the disease process. ALDER
et al. [55] showed that telomere length in alveolar epithelium
and peripheral blood leukocytes from patients with IPF was
significantly shortened. Shortened telomeres in these patients
occurred even in the absence of a family history or detectable
mutations in telomerase. The striking loss of cellular homeo-
stasis in IPF is notable for the increase in the number of
mesenchymal cells, including clusters of myofibroblasts within
the architecturally remodelled alveoli of the UIP lung. IPF is
primarily a disease of the elderly, with a remarkable increase
in incidence and prevalence beyond the fifth decade of life [56].
In the lung, the alveolar epithelial lining composed primarily
of flattened, differentiated alveolar type 1 (AT1) cells comprise
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.95% of the alveolar surface area and are replenished by its
tissue- and lineage-specific progenitors, the alveolar type 2
(AT2) cells. Lung-resident mesenchymal stem/progenitor cells
(MSCs) have only recently been identified, both in adult lung
of humans [57] and mice [58, 59]. As is true for adult tissue-
resident stem/progenitor cells (but not differentiated somatic
cells), both AT2 cells [60] and MSCs [59] express telomerase.
Telomere shortening is associated with reduced capacity for
stem cell renewal, cellular senescence, and organism aging
[61]. One might predict that telomere shortening in AT2 cells
would diminish regenerative capacity of the alveolar epithe-
lium. Another intriguing question that the study raises is why
the same host and environmental factors that presumably
suppress the regenerative capacity of epithelial stem cells do
not affect the mesenchymal response. This may be explained
by the observation that telomere length and telomerase activity
in stem/progenitor cells may be cell specific and autonomous
[62]. In fact, it is likely that cells within even the same stem cell
compartment may be influenced to varying degrees by the
cumulative, stochastic events that influence telomere length
and resultant regenerative capacity. This may also provide a
plausible explanation for the observed spatial–temporal
heterogeneity in UIP. Further studies are required to define
telomerase expressing cells in the lungs of patients with IPF as
well as telomere (dys)function in different stem cell compart-
ments and their resultant cellular phenotypes. Such studies
will aid in defining whether IPF represents a disorder of stem
cell senescence and impaired lung regeneration [63].
In a recent study, it was demonstrated for the first time that a
severe endoplasmic reticulum stress response in the AT2 cells
seems to underlie the execution of the intrinsic apoptosis
pathway, and thus the programmed cell death of this cell type,
in patients with sporadic IPF. Endoplasmic reticulum stress
response may represent an important trigger mechanism of the
aberrant fibrotic repair observed in IPF [64].
IPF is characterised by myofibroblast accumulation and
progressive lung scarring. Mesenchymal cells are responsible
for deposition of extracellular matrix proteins such as collagen
and fibronectin in the lung parenchyma and this compromises
gas exchange. These mesenchymal cells may arise from three
distinct sources. First, resident lung fibroblasts proliferate
and differentiate into myofibroblasts, prodigious producers
of collagen and contractile contributors to alveolar collapse
and traction bronchiectasis. The second source may involve
epithelial to mesenchymal transition, a process whereby epi-
thelial cells release from basement membrane and undergo
reprogramming that allows them to acquire a mesenchymal
phenotype [65]. The third source involves recruitment of
circulating bone marrow-derived precursors, known as fibro-
cytes, which share mesenchymal and leukocyte markers [66].
Significant increases in percentages of circulating fibrocytes
were found in both stable and acute cohorts with IPF when
compared with healthy volunteers, but the numbers were most
striking in patients with IPF-AE [67]. This study suggests that
the percentage of fibrocytes in circulation may serve as a
biomarker for the presence of fibrotic lung disease and may be
a useful biomarker for acute exacerbations [67]. Currently,
therapeutic trials in IPF are hampered by the lack of robust
easily obtained outcome variables for analysis and response to
therapy. Changes in FVC are used to predict disease severity but
may not reflect pathological changes in the disease process [3].
Serial analyses of fibrocytes may predict stability, deterioration
and/or acute exacerbation. Additionally, this recent study
indicates that fibrocyte percentages .5% are independent pre-
dictors of early mortality in IPF [67]. An ancillary study for the
IPF Network, ‘‘prednisone, azathioprine and N-acetylcysteine:
a three arm study that evaluates responses in IPF’’, or PANTHER
trial, will include an analysis of fibrocyte numbers and chemokine
receptor profiling at baseline, mid-point, and at the conclusion of
the study (weeks 0, 32, and 60) for up to 130 patients in each of
three study arms [68].
Normal lung development and alveologenesis, which may
continue into adolescence, are highly complex and regulated
processes that are dependent on epithelial/endothelial–
mesenchymal interactions. Although dormant in the uninjured
adult lung, many developmental pathways are reactivated in
the context of injury, repair and regeneration [69–71]. Together,
these studies highlight the role of conserved developmental
pathways in adult lung regeneration and support potential
opportunities to modulate the reparative process in patients
with DPLD.
NONSPECIFIC INTERSTITIAL PNEUMONIA
NSIP is often a source of diagnostic confusion. A recent study
clearly demonstrates that NSIP is a separate entity and nicely
determines its characteristics [72]. Key features of NSIP on
HRCT are bilateral, symmetrical, predominantly lower lung
reticular opacities with traction bronchiectasis and lower lobe
volume loss that is usually diffuse or sub-pleural in the axial
dimension but sometimes spares the sub-pleural lung [72]. If
typical HRCT features are sufficient to allow a confident
diagnosis of IPF/UIP in .50% of suspected cases, the HRCT
sensitivity and specificity in the NSIP diagnosis are lower;
there is overlap between the HRCT findings of UIP and those
of NSIP in several cases. It must be pointed out that a confident
diagnosis of NSIP requires surgical biopsy. A large proportion
of patients initially considered to have idiopathic NSIP were
subsequently reclassified as having hypersensitivity pneum-
onitis, IPF or organising pneumonia. When an HRCT scan
shows classical features of hypersensitivity pneumonitis or
organising pneumonia, these diagnoses are favoured over
idiopathic NSIP, even if a surgical lung biopsy shows
histological features of the NSIP pattern. Similarly, an HRCT
showing a typical pattern of UIP (in particular, honeycomb
changes) leads to a diagnosis of IPF, even when a surgical lung
biopsy shows histological features of NSIP [72]. The difficulties
inherent in trying to identify a discrete clinical, histological and
radiological phenotype for NSIP arise because NSIP represents
the common histological lesion of a range of diseases. NSIP is
one of the most common patterns of interstitial pneumonia, not
only in IIP, but also in patients with other disorders causing
interstitial pneumonia, such as connective tissue diseases
(CTDs), infection and drug or environmental toxicity. KINDER
et al. [73] reported that 88% of their cases of idiopathic NSIP
had manifestations of an undifferentiated CTD. In another
study, ,10% of the patients developed CTD during follow-up
and they were younger and had higher rheumatoid factor
positivity [74]. It was also found that honeycombing on the
initial HRCT, initial pulmonary function test and changes in
FVC at 12 months have considerable prognostic value [74].
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Whether idiopathic NSIP is an autoimmune disease needs
further investigations. In cases in which computed tomogra-
phy or biopsy are believed to show features of NSIP, but in
which there are incomplete data or suspicion of an alternative
diagnosis, such as hypersensitivity pneumonitis, the term
‘‘NSIP pattern’’ is appropriate [72]. Therefore, it is current
opinion that the integrative approach of clinical–radiological–
pathological data must be extended to the whole spectrum of
DPLD, as in all these disorders diagnosis is very complex, and
the same problems of sampling error and interobserver
variation between pathologists are encountered [72].
CONNECTIVE TISSUE DISEASE
A recent study confirmed that patients with CTD–interstitial
pneumonia survived longer than those with IIP, but this was
mainly because the survival of patients with CTD/UIP was
longer than those with IPF/UIP, and not just due to a higher
prevalence of a NSIP pattern in patients with CTDs (figs 4 and
5) [75]. In patients with a NSIP pattern as an overall group,
there was no survival benefit in the CTD/NSIP group
compared with the idiopathic NSIP group. Interestingly,
mortality in UIP was higher in rheumatoid arthritis than in
other CTDs and was only marginally lower than in IPF,
although the small size of the rheumatoid arthritis subgroup is
an important caveat [75]. UIP was more prevalent than NSIP in
this rheumatoid arthritis cohort, and, based on earlier reports
[76–78], appears to be much more prevalent in rheumatoid
arthritis than in other CTDs.
The Scleroderma Lung Study group reported that, after 1 yr of
placebo-controlled oral cyclophosphamide for pulmonary
fibrosis in systemic sclerosis (SSc), the benefits of active
treatment persisted at 6 months but not at 1 yr [79].
Importantly, the treatment benefit resulted in the prevention
of disease progression in more advanced fibrotic disease,
rather than regression of reversible inflammatory disease. One
obvious implication is that oral cyclophosphamide therapy
should be consolidated by a less toxic agent in the longer term.
Intravenous cyclophosphamide and oral mycophenolate mofe-
til have both been proposed as suitable longer term treatments,
or even as substitutes for the initial use of oral cyclophos-
phamide [80–83]. Although historically considered to provide
useful prognostic information in SSc, the presence of a BAL
neutrophilia was recently found in a large SSc cohort to be
linked only to early mortality and not to long-term survival or
the rapidity of pulmonary function decline [84]. In a prospective
study of 105 patients, only diffuse SSc was predictive of a
decrease in pulmonary function; this observation does not
support preliminary data suggestive of a causative role of
oesophageal involvement [85]. In a recent study, serum levels
of SP-D and KL-6, a mucin-like glycoprotein, appear to be
indicative of ‘‘alveolitis’’ in SSc patients, and are significantly
higher than in SSc patients without ‘‘alveolitis’’ [86]. Serum
SP-D and KL-6 may serve as noninvasive serological means of
assessing ILD in patients with SSc.
Hypersensitivity pneumonitis
Hypersensitivity pneumonitis, also termed extrinsic allergic
alveolitis, is a form of DPLD resulting from an aberrant
immunological response to an inhaled allergen in sensitised
patients. Currently, no ‘‘gold standard’’ exists for diagnosing
hypersensitivity pneumonitis, although identifying an inciting
antigen linked to exacerbation and remission of symptoms is
essential. A subset of patients with suspected hypersensitivity
pneumonitis lacks an identifiable antigenic exposure. Lung
biopsy plays an especially important role in identifying patients
for whom no offending antigen is discovered, particularly those
with chronic, persistent symptoms. Histological features that
allow confident recognition of hypersensitivity pneumonitis in
the appropriate clinical context include a bronchiolocentric
interstitial pneumonia comprising a combination of chronic
inflammation and variable degrees of fibrosis, chronic bronchi-
olitis and poorly formed granulomas that typically take the form
of isolated multinucleated giant cells within peribronchiolar
interstitium [87]. Occasionally, surgical lung biopsies may lack
diagnostic features, showing instead NSIP without associated
granulomatous inflammation. UIP also has been described in
patients with suspected hypersensitivity pneumonitis [88].
Surgical lung biopsy is helpful in separating hypersensitivity
pneumonitis from other forms of DPLD, including IIP. Late
stage hypersensitivity pneumonitis and UIP may be indis-
tinguishable in some patients [89]. The presence and the extent
of fibrosis on HRCT predicts survival in hypersensitivity
pneumonitis patients. Hypersensitivity pneumonitis may
resemble NSIP or UIP by both radiological and histopathologi-
cal assessment, and these appearances likely portend worse
prognosis [88, 90, 91]. Recently, SILVA et al. [92] demonstrated
that the computed tomography features that best differentiated
hypersensitivity pneumonitis from NSIP and UIP were lobular
areas with decreased attenuation, absence of lower zone
predominance, and presence of centrilobular nodules (fig. 6).
A recent study proposes that the clinical course of fibrotic
hypersensitivity pneumonitis, like other forms of fibrotic lung
disease, can be associated with idiopathic acute exacerbations
FIGURE 4. High-resolution computed tomography with nonspecific interstitial
pneumonia pattern in a patient with connective tissue disease; bilateral reticulation
and ground-glass are present. Although the abnormality shows peripheral
predominance in about one-third of cases, the relative sparing of the immediate
sub-pleural zone of lung seen in ,20% of cases may sometimes be a helpful
diagnostic finding.
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of disease leading to rapid respiratory deterioration and
predicting a poor outcome. Further investigations into the
similarities between these fibrotic lung diseases and the
(possible) common pathway of acute exacerbations may yield
additional insights into this recently recognised syndrome and,
possibly, a better understanding of the mechanisms of fibrosis
involved in these different disease processes [93].
LYMPHANGIOLEIOMYOMATOSIS
Lymphangioleiomyomatosis (LAM) is a rare lung disease
affecting females, with onset typically during the childbearing
years. LAM can occur in females with tuberous sclerosis
complex (TSC), an autosomal dominant disease characterised
by neurological disease (i.e. seizures, intellectual disability and
autism) and benign tumours of the brain, skin, heart and
kidneys. About 30% of females with TSC have evidence of
cystic lung disease on computed tomography scans and are
believed to have LAM (fig. 7). While the rate of progression is
variable, most females survive between 10 and 20 yrs after
diagnosis. Four natural history studies found that loss of
forced expiratory volume in 1 s (FEV1) averaged 75–156 mL
per year [94–97]. LAM varies in clinical features and rate of
progression; this, together with an absence of clear prognostic
factors, results in patients being given conflicting information
about prognosis. DL,CO, which is abnormal in more patients
than FEV1, may be a more sensitive indicator of early disease.
Patients with LAM may have partially reversible airflow
obstruction. A positive response to bronchodilators is asso-
ciated with an accelerated rate of decline in pulmonary
function [98]. Lung transplantation remains the only viable
option for end-stage disease. Several potential treatment
regimens directed at hormonal manipulation have proven
largely ineffective and the link between female sex and LAM
remains unexplained [96]. Pathologically, LAM is charac-
terised by two distinct components: LAM cells and cystic
areas of alveolar destruction. Smooth muscle (SM)-like LAM
cells represent a unique type of mesenchymal cell, expressing
SM-specific markers, continuously proliferating and invading
the lung parenchyma. Although the origin of LAM cells
a)
b)
FIGURE 5. Nonspecific interstitial pneumonia fibrosing pattern in a case of
connective tissue disease. a) The alveolar walls are thickened by interstitial fibrosis
and chronic inflammation. b) Hyperplasia of the lymphoid tissue is present.
a)
b)
FIGURE 6. a) High-resolution computed tomography shows innumerable ill-
defined centrilobular ground-glass opacity nodules, characteristic of sub-acute
hypersensitivity pneumonitis. Note that there are also foci of relative sparing
associated with air trapping. b) Evidence of fibrosis with irregular reticular opacities,
traction bronchiectasis and architectural distortion in chronic hypersensitivity
pneumonitis. A large cyst is present in the lower right lobe.
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remains unknown, some progress has been made in our
understanding of the genetics and signal transduction mechan-
isms regulating SM-like LAM cell proliferation and migration.
In the past few years, our understanding of the SM-like cells in
LAM has greatly improved. Abnormal growth, proliferation
and migration of atypical SM-like LAM cells in the lungs lead
to cystic destruction of the lungs. TSC1/TSC2 tumour
suppressor complex mutations had been linked to the
abnormal growth and migration of LAM cells. TSC2 dysfunc-
tion in LAM cells results in the constitutive activation of p70 S6
kinase (S6K1), which identifies S6K1 as a molecular target for
treatment of LAM disease [99–102]. In summary, it is apparent
that LAM cell behaviour, including growth, proliferation,
adhesion and motility, plays a critical role in LAM disease.
However, whether only TSC1 or TSC2 dysfunction accounts
for the multisystem pathological changes seen in pulmonary
LAM needs to be established. LAM pathology provides clues
to the enigmatic complexity of LAM disease, the solving of
which may lead not only to elucidating cellular and molecular
mechanisms but may also pave the way toward finding the
cure for LAM. The importance of further investigations into a
role of SM-like cells in the aetiology and pathology of LAM
cannot be overestimated, not only because they may uncover
mechanisms of LAM pathology but may also have the
potential to develop novel therapeutic strategies for LAM
treatment [102]. The role of mammalian target of rapamycin
(mTOR) inhibition in the therapy of patients with TSC and
LAM was recently investigated [103]. These rapid-fire
advances led to a prospective therapeutic trial in patients with
LAM and TSC with angiomyolipomas, with angiomyolipoma
volume as the primary end-point. Patients received 12 months
of rapamycin, followed by 12 months of follow-up after
discontinuation of rapamycin [104]. There was no randomisa-
tion or placebo control arm in this initial study. Of 25 males
and females enrolled, 20 patients completed 12 months of
rapamycin and 18 patients completed the full study, including
the 12 months of follow-up after rapamycin. Angiomyolipoma
volume decreased to 53% of baseline after 12 months of
rapamycin therapy, and after discontinuation increased to 86%
of baseline at 24 months. 18 of the patients had LAM, with 12
having TSC-associated LAM and six having sporadic LAM.
The improved lung function in the 10 females is extremely
encouraging, and perhaps unexpected: one might have
expected stabilisation of lung function, rather than improve-
ment, because the degradation of lung parenchyma that
accompanies LAM would not likely be correctable, at least
during 12 months of therapy with a TORC1 (mTOR complex 1)
inhibitor. Although the mechanisms of this improvement are
unknown, one possibility is that shrinkage or elimination of
LAM cells improves the elasticity and mechanics of the
residual areas of normal lung. Importantly, however, a second
study in the UK has reported interim results of a 24-month trial
of rapamycin for patients with TSC and LAM [105], and found
no evidence of improved FEV1 or FVC in the four females with
LAM who had completed 12 months of rapamycin. Possible
explanations for these differences include an unrecognised
difference in the severity or clinical parameters of LAM
between the Cincinnati and UK cohorts, which may be
amplified by the small numbers of patients, the impact of
dose reductions or cessations related to adverse events, and/or
the possibility of an effort-dependent placebo effect on the
results of pulmonary function testing. It is likely that clarity
will be provided when the completed data are available from
the UK trial and when results are available from the
Multicenter International LAM Efficacy of Sirolimus (MILES)
trial, the first prospective, randomised clinical trial in
pulmonary LAM, representing another landmark in the history
of LAM research [103]. This trial completed accrual in 2009. An
open-label, nonrandomised, within-subject dose escalation
safety, tolerability and efficacy study of everolimus (a second
generation mTOR inhibitor) in females with sporadic or TSC-
associated LAM is ongoing. A case report showed benefit from
doxycycline in a patient with LAM [106]. This case supports
the hypothesis that doxycycline may represent a promising
therapy for LAM. The evaluation of the role of doxycycline in
LAM therapy is ongoing. Recently, the European Respiratory
Society published consensus guidelines elaborated from a core
panel of specialists for the diagnosis and management of LAM
[107]. The recently established International LAM Registry is a
component of a set of web-based resources, including a patient
self-report data portal, aimed at accelerating research in rare
diseases in a rigorous fashion and demonstrates that a
collaboration between clinicians, researchers, advocacy groups
and patients can create an essential community resource
infrastructure to accelerate rare disease research [108].
PH IN DPLD
PH is prevalent and clinically relevant in various DPLDs [109–
111]. The incidence of PH in patients with IPF increases from
39% at the time of listing for lung transplantation to 78% at the
time of transplantation [112]. Among the 70 patients who
underwent right heart catheterisation (RHC) during their
initial workup, the prevalence of PH based on standard
criterion (mean pulmonary arterial pressure .25 mmHg)
was 8.1% (six patients) [113]. LETTIERI et al. [114] reported a
markedly higher prevalence of 31.6% among IPF patients who
underwent the evaluation while waiting for lung transplanta-
tion. In estimations of pulmonary arterial pressure by NADROUS
et al. [115] using the ultrasound cardiography (USCG) method,
systolic pulmonary arterial pressures .50 mmHg were present
FIGURE 7. High-resolution computed tomography (HRCT) showing typical
changes in a patient with advanced definite lymphangioleiomyomatosis: extensive
cystic changes are present. HRCT shows numerous discrete, round, thin-walled
lung cysts.
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in 30.7% of patients. Differences in the populations and
measuring methods in these three studies make it difficult to
directly compare the prevalence of PH. Generally, the degree
of PH in IPF is mild to moderate, with few subjects developing
severe PH by the time of listing for lung transplant. Elevated
concentrations of N-terminal pro-brain natriuretic peptide
levels and low DL,CO [116] may be predictive of the presence
of PH in DPLDs. Studies from the past few years [114, 115]
have shown that PH measured with RHC or USCG in IPF
patients is associated with low DL,CO, shorter walk distances
and desaturation during exercise. Similar relationships have
been identified when brain natriuretic peptide was used as a
surrogate marker for PH in IPF patients [117]. The optimal
approach to identifying which IPF patients have PH remains
controversial, however. Nevertheless, increasing PH is asso-
ciated with an increasing risk of death in IPF patients [114,
115], while elevated pre-operative PH may contribute to post-
transplant mortality in IPF [118, 119]. Factors other than the
extent of fibrosis appear to play a significant role in the genesis
of PH in patients with IPF. These might include, but are not
necessarily limited to, local or systemic hypoxaemia, pulmon-
ary thromboembolism, cardiac dysfunction, genetic predis-
position, and variable cytokine or chemokine expression.
The aetiology and course of PH in IPF warrants further study,
as do therapies directed at preventing or treating this common
complicating comorbidity [120]. With the advent of newer
options for treating PH, coupled with the lack of effective
therapies for IPF, therapy for disproportionate PH (PH
associated with DPLD with a median pulmonary arterial
pressure level above the usual values) appears an attractive
area of investigations.
One important point in recent years in the field of smoking-
induced chronic lung disease has been the identification of the
syndrome of combined pulmonary fibrosis and emphysema
(CPFE) [121]. Not just a distinct phenotype of IPF, the
syndrome of CPFE is characterised by the association of
distinct features, including tobacco smoking, severe dyspnoea,
unexpected subnormal spirometry, severely impaired DL,CO,
hypoxaemia on exercise, and characteristic imaging features
(centrilobular and/or paraseptal emphysema, and diffuse
interstitial opacities suggestive of pulmonary fibrosis of the
lower lobes). The pathological features have not yet been
formally studied. Pathophysiology of the syndrome beyond
the obvious role of tobacco smoking remains to be explored
[122]. Suspected in patients with dyspnoea and basal crackles
unexplained by spirometry, the syndrome of CPFE can be
recognised by the presence of both ‘‘significant’’ emphysema
and fibrosis features on HRCT of the chest (fig. 8). Importantly,
patients with the syndrome of CPFE have a high probability of
severe pre-capillary PH [121], which carries a poor prognosis,
with only 60% survival at 1 yr from the date of RHC [123].
Indeed, the risk of developing PH is notably higher in CPFE
than in IPF without emphysema [124] and PH (and not only
the presence of associated emphysema) represents the main
independent determinant of mortality in patients with CPFE
[121, 124].
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